Post‐Treatment Movement Disorder in a Child with Late‐onset Cobalamin Deficiency

2021 ◽  
Author(s):  
Ala Fadilah ◽  
Peter S. Baxter ◽  
Ptolemaios G. Sarrigiannis ◽  
Soma Sengupta ◽  
Mark J. Sharrard ◽  
...  
Keyword(s):  
Movement Disorder ◽  
Late Onset ◽  
Post Treatment ◽  
Cobalamin Deficiency

scholarly journals Preserved Serotonergic Activity in Early-Onset Parkinson’s Disease

2019 ◽  
Vol 47 (3) ◽  
pp. 344-349 ◽  
Author(s):  
Hee Kyung Park ◽  
Jae-Jung Lee ◽  
Young-Min Park
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Onset ◽  
Auditory Evoked Potentials ◽  
Late Onset ◽  
Post Treatment ◽  
Dopaminergic Medication ◽  
Serotonergic Activity ◽  
The Absolute ◽  
Onset Group

ABSTRACT:Background:Serotonergic dysfunction may play an important role in motor and nonmotor symptoms of Parkinson’s disease (PD). The loudness dependence of auditory evoked potentials (LDAEP) has been used to evaluate serotonergic activity. Therefore, this study aimed to determine central serotonergic activity using LDAEP in de novo PD according to the age at onset and changes in serotonergic activity after dopaminergic treatment.Methods:A total of 30 patients with unmedicated PD, 16 in the early-onset and 14 in the late-onset groups, were enrolled. All subjects underwent comprehensive neurological examination, laboratory tests, the Unified Parkinson’s Disease Rating Scale, and LDAEP. The LDAEP was calculated as the slope of the two N1/P2 peaks measured at the Cz electrode, first at baseline conditions (pretreatment) and a second time after 12 weeks (post-treatment) following dopaminergic medications.Results:The absolute values of pretreatment N1/P2 LDAEP (early-onset: late-onset, 0.99 ± 0.68: 1.62 ± 0.88, p = 0.035) and post-treatment N1 LDAEP (early-onset: late-onset, −0.61 ± 0.61: −1.26 ± 0.91, p = 0.03) were significantly lower in the early-onset group compared with those of the late-onset group. In addition, a higher value of pretreatment N1/P2 LDAEP was significantly correlated with the late-onset group (coefficient = 1.204, p = 0.044). The absolute value of the N1 LDAEP decreased after 12 weeks of taking dopaminergic medication (pretreatment: post-treatment, −1.457 ± 1.078: −0.904 ± 0.812, p = 0.0018).Conclusions:Based on the results of this study, LDAEP could be a marker for serotonergic neurotransmission in PD. Central serotonergic activity assessed by LDAEP may be more preserved in early-onset PD patients and can be altered with dopaminergic medication.

The Expression of Schizophrenia, Affective Disorder and Vulnerability to Tardive Dyskinesia in an Extensive Pedigree

1988 ◽  
Vol 153 (3) ◽  
pp. 376-381 ◽  
Author(s):  
John L. Waddington ◽  
Hanafy A. Youssef
Keyword(s):  
Family History ◽  
Tardive Dyskinesia ◽  
Movement Disorder ◽  
Affective Disorder ◽  
Psychiatric Illness ◽  
Late Onset ◽  
Psychiatric Morbidity ◽  
Neuroleptic Treatment ◽  
History Of

The demography, psychiatric morbidity, and motor consequences of long-term neuroleptic treatment in the 14 children born to a father with a family history of chronic psychiatric illness and a mother with a late-onset affective disorder resulting in suicide are documented. Twelve siblings lived to adulthood, nine of whom were admitted to a psychiatric hospital in their second or third decade, and required continuous in-patient care; five remaining in hospital, with long-term exposure to neuroleptics, had chroniC., deteriorating, schizophrenic illness and emergence of movement disorder. Two siblings showed no evidence of psychosis but developed a late-onset affective disorder. The implications for the issues of homotypia, vulnerability to involuntary movements, and interaction with affective disorder are discussed.

P591: Late onset myopathy and hyperkinetic movement disorder

2014 ◽  
Vol 125 ◽  
pp. S209
Author(s):  
D. Hopmann ◽  
A. Kivi ◽  
W. Stenzel ◽  
R. Ehret ◽  
J. Mueller
Keyword(s):  
Movement Disorder ◽  
Late Onset ◽  
Hyperkinetic Movement Disorder

scholarly journals Midbrain/pons area ratio and clinical features predict the prognosis of Progressive Supranuclear Palsy

2020 ◽  
Author(s):  
shishuang cui ◽  
huawei ling ◽  
juanjuan du ◽  
yiqi lin ◽  
jing pan ◽  
...  
Keyword(s):  
Progressive Supranuclear Palsy ◽  
Movement Disorder ◽  
Late Onset ◽  
Age At Onset ◽  
Early Death ◽  
Area Ratio ◽  
Cox Proportional Hazard ◽  
Kaplan Meier ◽  
History Of

Abstract Backgrounds: Progressive Supranuclear Palsy (PSP) is a rare movement disorder with poor prognosis. This retrospective study aims to characterize the natural history of PSP and to find predictors of shorter survival and faster decline of activity of daily living. Method: All patients recruited fulfilled the movement disorder society (MDS) clinical diagnostic criteria for PSP (MDS-PSP criteria) for probable and possible PSP with median 12 years. Data were obtained including age, sex, date of onset, age at onset (AAO), symptoms reported at first visit and follow-up, date of death and date of institutionalization. Magnetic resonance imaging was collected at the first visit. Endpoints were death and institutionalization. Kaplan-Meier method and Cox proportional hazard model were used to explore factors associated with early death and institutionalization. Results: 59 patients fulfilling MDS-PSP criteria were enrolled in our study. 19 patients (32.2%) had died and 31 patients (52.5%) were institutionalizedl by the end of the follow-up. Predictors associated with poorer survival were late-onset PSP and decreased M/P area ratio. Predictors associated with earlier institutionalization were older AAO and decreased M/P area ratio. Conclusion: older and decreased M/P area ratio were predictors for earlier dearth and institutionalization in PSP. The neuroimaging biomarker M/P area ratio was a predictor for prognosis in PSP.

scholarly journals Midbrain/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy

BMC Neurology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Shi-Shuang Cui ◽  
Hua-Wei Ling ◽  
Juan-Juan Du ◽  
Yi-Qi Lin ◽  
Jing Pan ◽  
...  
Keyword(s):  
Progressive Supranuclear Palsy ◽  
Movement Disorder ◽  
Late Onset ◽  
Age At Onset ◽  
Early Death ◽  
Area Ratio ◽  
Cox Proportional Hazard ◽  
Kaplan Meier ◽  
History Of

Abstract Background Progressive supranuclear palsy (PSP) is a rare movement disorder with poor prognosis. This retrospective study aimed to characterize the natural history of PSP and to find predictors of shorter survival and faster decline of activity of daily living. Method All patients recruited fulfilled the movement disorder society (MDS) clinical diagnostic criteria for PSP (MDS-PSP criteria) for probable and possible PSP with median 12 years. Data were obtained including age, sex, date of onset, age at onset (AAO), symptoms reported at first visit and follow-up, date of death and date of institutionalization. Magnetic resonance imaging was collected at the first visit. Endpoints were death and institutionalization. Kaplan-Meier method and Cox proportional hazard model were used to explore factors associated with early death and institutionalization. Results Fifty-nine patients fulfilling MDS-PSP criteria were enrolled in our study. Nineteen patients (32.2%) had died and 31 patients (52.5%) were institutionalized by the end of the follow-up. Predictors associated with poorer survival were late-onset PSP and decreased M/P area ratio. Predictors associated with earlier institutionalization were older AAO and decreased M/P area ratio. Conclusion Older AAO and decreased M/P area ratio were predictors for earlier dearth and institutionalization in PSP. The neuroimaging biomarker M/P area ratio was a predictor for prognosis in PSP.

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8525-8525 ◽  
Author(s):  
O. Hamid ◽  
W. J. Urba ◽  
M. Yellin ◽  
G. M. Nichol ◽  
J. Weber ◽  
...  
Keyword(s):  
Treatment Initiation ◽  
Cytotoxic T Lymphocyte ◽  
Late Onset ◽  
Human Monoclonal Antibody ◽  
Peptide Vaccine ◽  
Post Treatment ◽  
The Other ◽  
Stage Iii ◽  
Duration Of Response ◽  
Kinetics Of

8525 Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), enhances immune responses to tumor-associated antigens resulting in durable objective responses (OR). This abstract describes the kinetics of response after ipilimumab treatment. Methods: 5 studies (2 complete; 3 ongoing) in 269 treated patients with stage III/IV melanoma were reviewed and analyzed to determine the kinetics and duration of response after ipilimumab. Patients received ipilimumab alone or with dacarbazine, IL-2 or gp100 peptide vaccine. Ipilimumab doses ranged from 0.3–10mg/kg/dose (single or multiple). Complete and partial response (CR, PR), stable and progressive disease (SD, PD) were evaluated. Results: 41 patients (15%) had a confirmed OR at analysis. CR and PR was of late onset in some patients and occurred from ∼10–106 and ∼5–62 weeks (w) post-treatment initiation, respectively. In 28 patients onset of CR or PR occurred after >∼12w of treatment. PD preceded OR (without additional therapy) in 4 patients. In 2 patients, PD measured at ∼6w post-treatment initiation was followed by a PR at ∼12w. In 1 patient the PR changed to a CR at ∼24w and lasted for ∼188w+; the other patient maintained a PR for ∼17w. In the other 2 patients, PD at ∼12w was followed by SD at ∼17–20w and a PR after ∼30 and 62w; PRs in both patients lasted for ∼17 and 40w+, respectively. Duration of OR ranged from ∼6–187w+; ORs are ongoing in 25 patients. Late onset occurred irrespective of dose, regimen and therapeutic partner. Conclusions: Preliminary results suggest that ORs with ipilimumab may be later in onset and more durable than with traditional chemotherapy and may occur after progression. This late onset of effect likely reflects the immune-related mechanism of action of ipilimumab, and suggests that continued treatment/observation may be beneficial despite initial PD or SD. Acknowledgement: Dr. S. Rosenberg [Table: see text]

scholarly journals Midbrain/pons area ratio and clinical features predict the prognosis of Progressive Supranuclear Palsy

2020 ◽  
Author(s):  
Shishuang Cui ◽  
Huawei Ling ◽  
Juanjuan Du ◽  
Yiqi Lin ◽  
Jing Pan ◽  
...  
Keyword(s):  
Progressive Supranuclear Palsy ◽  
Movement Disorder ◽  
Late Onset ◽  
Age At Onset ◽  
Early Death ◽  
Area Ratio ◽  
Cox Proportional Hazard ◽  
Kaplan Meier ◽  
History Of

Abstract Backgrounds: Progressive Supranuclear Palsy (PSP) is a rare movement disorder with poor prognosis. This retrospective study aims to characterize the natural history of PSP and to find predictors of shorter survival and faster decline of activity of daily living. Method: All patients recruited fulfilled the movement disorder society (MDS) clinical diagnostic criteria for PSP (MDS-PSP criteria) for probable and possible PSP with median 12 years. Data were obtained including age, sex, date of onset, age at onset (AAO), symptoms reported at first visit and follow-up, date of death and date of institutionalization. Magnetic resonance imaging was collected at the first visit. Endpoints were death and institutionalization. Kaplan-Meier method and Cox proportional hazard model were used to explore factors associated with early death and institutionalization. Results: 59 patients fulfilling MDS-PSP criteria were enrolled in our study. 19 patients (32.2%) had died and 31 patients (52.5%) were institutionalizedl by the end of the follow-up. Predictors associated with poorer survival were late-onset PSP and decreased M/P area ratio. Predictors associated with earlier institutionalization were older AAO and decreased M/P area ratio. Conclusion: older and decreased M/P area ratio were predictors for earlier dearth and institutionalization in PSP. The neuroimaging biomarker M/P area ratio was a predictor for prognosis in PSP.

scholarly journals Guanidinoacetate methyltransferase (GAMT) deficiency: late onset of movement disorder and preserved expressive language

2009 ◽  
Vol 51 (5) ◽  
pp. 404-407 ◽  
Author(s):  
DECLAN J O’ROURKE ◽  
STEPHANIE RYAN ◽  
GAJJA SALOMONS ◽  
CORNELIS JAKOBS ◽  
AHMAD MONAVARI ◽  
...  
Keyword(s):  
Movement Disorder ◽  
Late Onset ◽  
Expressive Language ◽  
Gamt Deficiency

scholarly journals DOPA-sparing strategy in the treatment of young onset Parkinson’s disease

2016 ◽  
Vol 7 (01) ◽  
pp. 67-69 ◽  
Author(s):  
Abdul Qayyum Rana ◽  
Mohamad Saleh ◽  
Muhammad Saad Yousuf ◽  
Wasim Mansoor ◽  
Syed Hussaini ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Disorder ◽  
Neurodegenerative Disorder ◽  
Late Onset ◽  
Retrospective Chart Review ◽  
Cross Sectional Study ◽  
Community Based ◽  
Cross Sectional ◽  
Young Onset

ABSTRACT Context: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the trend in the choice of drug administered to patients with both YOPD and LOPD, with particular emphasis on this trend in its relation to the practice background of the neurologist. Settings and Design: A cross-sectional study was conducted in a community based Parkinson’s disease and movement disorder clinic. Statistical Analysis Used: Using a retrospective chart review data was obtained and analysed. Results: The results showed that 83% of general neurologists prescribed levodopa to their patients with YOPD, whereas movement-disorder specialists took a different approach altogether. They opted not to use levodopa and, in its stead, prescribed a mixture of alternate drugs.

Sign in / Sign up

Export Citation Format

Share Document